INNOVADERM CRO IS NOW INDERO.

Leading Clinical Research in Europe

With over 25 years of specialized experience in dermatology and rheumatology, Indero, formerly known as Innovaderm, is a leading full-service Contract Research Organization (CRO) and a trusted partner in clinical development.

We provide full operational support across all phases of clinical trials, leveraging scientific rigor, therapeutic expertise, and innovative methodologies to drive
high-quality outcomes and advance patient care.

circle_bg_out.png
circle_bg_out.png

The Only Dermatology and Rheumatology Dual Focus CRO In Europe

Our European presence is anchored by 3 key operational hubs in Poland, Germany, and Spain, enabling seamless trial execution and regulatory navigation across the continent. We extend our reach to all European countries, ensuring local expertise, cultural alignment, and operational agility wherever you need us.

Duong Nguyen

Head of Clinical Operations at Inmagene Biopharmaceuticals.

“Working with Indero for our alopecia areata trial has been a smooth
and exceptional experience, marked by their extensive expertise,
proactive approach, and seamless collaboration.”

Innovaderm’s profound understanding of alopecia areata and their forward-thinking strategy sets them apart. The team’s detailed explanations, thorough research, and well-considered solutions are commendable, especially in risk mitigation. Our collaboration with Innovaderm has been smooth and cooperative, free from finger-pointing or difficult interactions. Both teams have meshed well, working together towards the best outcomes for the study and the patients. It has been a pleasure, and we look forward to many more successful studies together. We highly recommend Innovaderm for their professionalism and expertise.

Managing Studies in Europe

Since 2017

Our Achievements

Purely Organic Footprint Across Europe

Our organic growth is a testament to our commitment to building a robust and independent presence across the continent, achieved without acquisitions.

15

AVERAGE YEARS OF INDUSTRY EXPERIENCE

HANDPICKED EXCELLENCE​

Our team members are meticulously selected to ensure they embody our high standards and core values, fostering a culture of excellence and integrity.​

260+

TRUSTED EUROPEAN DERMATOLOGY KEY OPINION LEADERS (KOLs)

LOCAL EXPERTISE, GLOBAL IMPACT​

Our European team leverages local expertise to drive innovation and success, making a significant impact on our global footprint.​

3,100

SITES

INVESTIGATORS IN OUR DATABASE (& GROWING)

Strategic site selection for dermatology & rheumatology clinical trials, based on relevant experience in your indication, positive indicators in efficacy assessments, and proven recruitment track records.

As your dermatology CRO, Indero provides expertise across a range of dermatological indications. Our team comprehends the intricacies of skin-related conditions, applying depth and precision to each study we support, including:

  • Atopic dermatitis
  • Psoriasis
  • Alopecia areata
  • Hidradenitis suppurativa
  • Chronic inducible urticaria
  • Chronic spontaneous urticaria
  • Vitiligo
  • Acne
  • Rosacea
  • Chronic hand eczema
  • Notalgia paresthetica
  • Actinic keratosis
  • GPP, PPP and PPPP
  • Hyperhidrosis
  • Prurigo nodularis
  • Onychomycosis
  • Cosmetics and aesthetics

As your rheumatology CRO, Indero offers the expertise to advance a broad spectrum of indications. Our team understands the complexities and unique demands of immune-mediated diseases, bringing depth and precision to every study we support, including:

  • Rheumatoid Arthritis (RA)
  • Osteoarthritis (OA)
  • Scleroderma/systemic sclerosis (SSc)
  • Psoriatic Arthritis (PsA) and Juvenile PsA
  • Systemic Lupus Erythematosus (SLE) and Juvenile SLE
  • Lupus Nephritis
  • Osteoporosis
  • Idiopathic Inflammatory Myopathies (IIM), including Dermatomyositis (DM), polymyositis (PM), and juvenile inflammatory myopathies (JIIMs)
  • Radiographic axial Spondyloarthritis (r-axSpA)
    (Ankylosing Spondylitis (AS))
  • Gout
  • Fibromyalgia
  • Behçet’s Disease
  • Sjögren’s Disease and juvenile Sjögren’s Disease
  • Non-radiographic axial Spondyloarthritis (nr-axSpA)
  • Anti-neutrophil cytoplasmic antibody (ANCA)/Associated vasculitides (AAVs)
  • Polymyalgia rheumatica
  • Giant cell arteritis
  • IgG4-related disease (IgG4-RD)

European KOL Testimonial

A Selection of Our European Team

Indero boasts a team of over 65+ and growing skilled professionals across Czech Republic, France, Germany, Hungary, Netherlands, Poland, Serbia, Spain, and the United Kingdom.

Recent Insights

Innovaderm to Indero
Podcast

Episode 40: Diane Leclerc – Leading from the Ground Up: Strategy, Transition, and Team Accountability

News

Indero to Participate in the DIF Entrepreneur Bootcamp in Denver

Case Study

Systemic Sclerosis Case Study

Wherever
You’re Going,
We’re all in.

Need help with your next study? We want to learn more. Fill out the form on the right and one of our experts will be in touch.

Jeff Smith

Chef de la direction

Jeff Smith, Chef de la direction d’Indero Recherches, apporte près de 30 ans d’expérience dans l’industrie pharmaceutique et CRO, s’étant distingué par son leadership exceptionnel, sa vision stratégique et son innovation. L’expertise de Jeff couvre des opérations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matière de création de valeur, de gestion des partenaires et d’opérations CRO ont toujours contribué au succès dans ses fonctions précédentes. Sous la direction de Jeff, Indero continue d’étendre ses capacités, faisant progresser les connaissances médicales et les nouvelles thérapies en dermatologie et en rhumatologie.

Revolutionize Your Topical Trials

Efficacy insights in days, not months.

 Indero’s Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8–12 weeks to ≤3 days, and lowers costs, helping teams make informed go/no-go decisions faster.